Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: A therapeutic target of PPARγ

American Journal of Pathology

Volumn 178, Issue 5, 2011, Pages 2020-2031

  Zhu, Chunhua ^a   Huang, Songming ^a   Yuan, Yanggang ^a   Ding, Guixia ^a   Chen, Ronghua ^a   Liu, Bicheng ^b   Yang, Tianxin ^c   Zhang, Aihua ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALDOSTERONE; CYTOCHROME C OXIDASE; EPLERENONE; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; NEPHRIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROSIGLITAZONE; ROTENONE; SMALL INTERFERING RNA; UBIQUINOL CYTOCHROME C REDUCTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL PROTECTION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; COPY NUMBER VARIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON TRANSPORT; ENZYME ACTIVITY; ENZYME SYNTHESIS; GENE OVEREXPRESSION; GLOMERULUS; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; RESPIRATORY CHAIN;

EID: 79959238107     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.01.029     Document Type: Article

References (46)

1. Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996, 98:1063-1068 (Pubitemid 26293326)
2. Epstein M: Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 2001, 37: 677-688
3. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T: Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007, 49:355-364 (Pubitemid 46143013)
4. Kiyomoto H, Rafiq K, Mostofa M, Nishiyama A: Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury. J Pharmacol Sci 2008, 108:399-405
5. Epstein M: Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006, 119:912-919
6. Zhang A, Jia Z, Guo X, Yang T: Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. Am J Physiol Renal Physiol 2007, 293:F723-F731 (Pubitemid 47403342)
7. Sato A, Hayashi K, Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005, 18:44-49 (Pubitemid 40187348)
8. Ambroisine ML, Milliez P, Nehme J, Pasquier AL, De Angelis N, Mansier P, Swynghedauw B, Delcayre C: Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy. Diabetes Metab 2004, 30:311-318 (Pubitemid 39280229)
9. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T: Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006, 47:1084-1093 (Pubitemid 44289165)
10. Nagata M, Yamaguchi Y, Ito K: Loss of mitotic activity and the expression of vimentin in glomerular epithelial cells of developing human kidneys. Anat Embryol (Berl) 1993, 187:275-279 (Pubitemid 23128035)
11. Hagiwara M, Yamagata K, Capaldi RA, Koyama A: Mitochondrial dysfunction in focal segmental glomerulosclerosis of puromycin aminonucleoside nephrosis. Kidney Int 2006, 69:1146-1152
12. Kriz W, Lemley KV: The role of the podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens 1999, 8:489-497 (Pubitemid 30004174)
13. Iglesias P, Diez JJ: Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol 2006, 154:613-621 (Pubitemid 43810845)
14. Yang HC, Ma LJ, Ma J, Fogo AB: Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 2006, 69:1756-1764 (Pubitemid 43739202)
15. Wilson-Fritch L, Burkart A, Bell G, Mendelson K, Leszyk J, Nicoloro S, Czech M, Corvera S: Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol Cell Biol 2003, 23:1085-1094 (Pubitemid 36133524)
16. Wilson-Fritch L, Nicoloro S, Chouinard M, Lazar MA, Chui PC, Leszyk J, Straubhaar J, Czech MP, Corvera S: Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 2004, 114:1281-1289 (Pubitemid 40385299)
17. Schutz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, Schurmann B, Zimmer A, Heneka MT: The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 2005, 25:7805-7812 (Pubitemid 41208652)
18. Quintanilla RA, Jin YN, Fuenzalida K, Bronfman M, Johnson GV: Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J Biol Chem 2008, 283:25628-25637
19. Mundel P, Reiser J, Kriz W: Induction of differentiation in cultured rat and human podocytes. J Am Soc Nephrol 1997, 8:697-705 (Pubitemid 27493583)
20. Huang JH, Lu L, Lu H, Chen X, Jiang S, Chen YH: Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1. J Biol Chem 2007, 282:6143-6152 (Pubitemid 47100832)
21. Katsuya K, Yaoita E, Yoshida Y, Yamamoto Y, Yamamoto T: An improved method for primary culture of rat podocytes. Kidney Int 2006, 69:2101-2106 (Pubitemid 43924277)
22. Huang S, Zhang A, Ding G, Chen R: Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation. Am J Physiol Renal Physiol 2009, 296:F1323-F1333
23. Deegens JK, Dijkman HB, Borm GF, Steenbergen EJ, van den Berg JG, Weening JJ, Wetzels JF: Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int 2008, 74:1568-1576
24. Wu JS, Lin TN, Wu KK: Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins. J Cell Physiol 2009, 220:58-71
25. Ikeuchi M, Matsusaka H, Kang D, Matsushima S, Ide T, Kubota T, Fujiwara T, Hamasaki N, Takeshita A, Sunagawa K, Tsutsui H: Overexpression of mitochondrial transcription factor a ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction. Circulation 2005, 112:683-690 (Pubitemid 41099047)
26. Whaley-Connell A, DeMarco VG, Lastra G, Manrique C, Nistala R, Cooper SA, Westerly B, Hayden MR, Wiedmeyer C, Wei Y, Sowers JR: Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury. Am J Nephrol 2008, 28:67-75 (Pubitemid 350126495)
27. Whaley-Connell AT, Chowdhury NA, Hayden MR, Stump CS, Habibi J, Wiedmeyer CE, Gallagher PE, Tallant EA, Cooper SA, Link CD, Ferrario C, Sowers JR: Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2006, 291:F1308-F1314 (Pubitemid 44887244)
28. Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez G, Inestrosa NC, Bronfman M: Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 2007, 282: 37006-37015
29. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM: Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999, 98:115-124 (Pubitemid 29331201)
30. de Haan JB, Stefanovic N, Nikolic-Paterson D, Scurr LL, Croft KD, Mori TA, Hertzog P, Kola I, Atkins RC, Tesch GH: Kidney expression of glutathione peroxidase-1 is not protective against streptozotocin-induced diabetic nephropathy. Am J Physiol Renal Physiol 2005, 289:F544-F551 (Pubitemid 41208469)
31. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T: Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006, 17:3438-3446 (Pubitemid 44865286)
32. Chance B, Sies H, Boveris A: Hydroperoxide metabolism in mammalian organs. Physiol Rev 1979, 59:527-605 (Pubitemid 9236599)
33. Bandy B, Davison AJ: Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging?. Free Radic Biol Med 1990, 8:523-539 (Pubitemid 20204417)
34. Turrens JF, Alexandre A, Lehninger AL: Ubisemiquinone is the electron donor for superoxide formation by complex III of heart mitochondria. Arch Biochem Biophys 1985, 237:408-414 (Pubitemid 15144894)
35. Semenkovich CF: Insulin resistance and atherosclerosis. J Clin Invest 2006, 116:1813-1822
36. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stadtman ER: Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990, 186:464-478
37. Muscari C, Guarnieri C, Biagetti L, Finelli C, Caldarera CM: Influence of age on oxidative damage in mitochondria of ischemic and reperfused rat hearts. Cardioscience 1990, 1:275-278
38. Birch-Machin MA: The role of mitochondria in ageing and carcinogenesis. Clin Exp Dermatol 2006, 31:548-552
39. Passos JF, von Zglinicki T, Saretzki G: Mitochondrial dysfunction and cell senescence: cause or consequence? Rejuvenation Res 2006, 9:64-68
40. Pamplona R, Barja G: Mitochondrial oxidative stress, aging and caloric restriction: the protein and methionine connection. Biochim Biophys Acta 2006, 1757:496-508 (Pubitemid 43993832)
41. Mannella CA: Structure and dynamics of the mitochondrial inner membrane cristae. Biochim Biophys Acta 2006, 1763:542-548
42. Yu T, Robotham JL, Yoon Y: Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology, Proc Natl Acad Sci USA 2006, 103:2653-2658
43. Solin ML, Pitkanen S, Taanman JW, Holthofer H: Mitochondrial dysfunction in congenital nephrotic syndrome. Lab Invest 2000, 80: 1227-1232 (Pubitemid 30637062)
44. Holthofer H, Kretzler M, Haltia A, Solin ML, Taanman JW, Schagger H, Kriz W, Kerjaschki D, Schlondorff D: Altered gene expression and functions of mitochondria in human nephrotic syndrome. FASEB J 1999, 13:523-532 (Pubitemid 29115570)
45. Lin JD: Minireview: the PGC-1 coactivator networks: chromatin-remodeling and mitochondrial energy metabolism. Mol Endocrinol 2009, 23:2-10
46. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM: A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998, 92:829-839 (Pubitemid 28155321)